Aurobindo Pharma unit partners with MSD to foray into contract manufacturing operations
Hyderabad: Drug firm, Aurobindo Pharma has said that TheraNym Biologics, a wholly-owned subsidiary of the Company and an affiliate of CuraTeQ, has entered into agreement with MSD to establish a plant as it looks to enter the contract manufacturing operations for biologicals. TheraNym Biologics and MSD, signed a Master Service Agreement (MSA).
In October last year, CuraTeQ Biologics and Merck Sharp & Dohme Singapore Trading Pte Ltd and its affiliates (MSD) signed a letter of intent for contract manufacturing operations involving biologicals. Originally, the parties aimed to finalize negotiations by March 31, 2024. However, they later agreed to extend the deadline until May 31.
Read also: Aurobindo Pharma commissions 4 manufacturing plants for PenicillinG, other products
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries. The Company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, AntiRetroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.
Read also: Aurobindo Pharma appoints T Vijaya Kumar as President - RnD (Specialty Drug Delivery)
